STAT3 and head and neck squamous cell carcinoma: Hsu and colleagues treated the radio-resistant HNSCC cell lines SCC-22A and SCC-22B, which both express constitutively activated STAT3 at high levels, with the multi-receptor tyrosine kinase inhibitor linifanib (ABT-869).